



Valcyte® (valganciclovir) oral solution – First-Time Generic

- On August 29, 2016, Actavis launched an [AB-rated](#) generic version of Genentech's [Valcyte \(valganciclovir\)](#) 50 mg/mL oral solution.
 - Valcyte is also available generically as a 450 mg oral tablet.
- Valcyte is indicated for the following:
 - treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS)
 - prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk
 - prevention of CMV disease in kidney transplant patients (4 months -- 16 years of age) and heart transplant patients (1 month -- 16 years of age) at high risk
- Valcyte carries a boxed warning for hematologic toxicity, impairment of fertility, fetal toxicity, mutagenesis and carcinogenesis.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.